Effective anticancer agents based-on two Pillar[5]arene derivatives for pancreas cancer cell lines: synthesis, apoptotic effect, caspase pathway

A half-natural origin approach for anticancer and antioxidant activities using sporopollenin and pillar[5]arene macroring

Sporopollenin is a natural biomacromolecule which can be found in the outer wall (exine) of spores or pollens that it can be performed with clever designing in a lot of innovative and scientific areas. In this paper, a novel sporopollenin reformed with a recently synthesized pillar[5]arene molecule were elucidated by FT-IR spectroscopy, TGA and SEM techniques. This study is the first report leading to a comprehensive investigation of the biological applications of a functionalized bio-microcapsule including antioxidant and anticancer properties. Two in vitro assays (DPPH and FRAP) were used to determine the antioxidant activities of sporopollenin and functionalized microcapsules. Furthermore, the anticancer activities of these microcapsules were tested on 2 different cancer cell lines (HT-29 and MCF-7), and a fibroblast cell line (L929) by the Alamar blue assay. Among the samples tested in the antioxidant capacity results, especially Sp-P[5] exhibited higher antioxidant capacity and stood out with IC50: 101.98 ± 4.32 μg/mL in DPPH assay and IC50: 87.97 ± 3.14 μg/mL in FRAP assay. Similar to the antioxidant result, Sp-P[5] bio-microcapsule had greater cell inhibition on HT-29 (IC50: 132.31 ± 5.38 μg/mL), MCF-7 (IC50: 107.30 ± 8.28 μg/mL), and L929 (IC50: 255.80 ± 4.91 μg/mL) cell lines than Sp and Sp-APTMS. The analysis results in the study show promise for the development of sporopollenin-based microcapsules to deliver and enhance the biological activity of compounds with therapeutic potential.

CRADD and cIAP1 antagonistically regulate caspase-9-mediated apoptosis in teleost

Caspase 9 (CASP9) is a well-known initiator caspase of intrinsic apoptosis. In humans, cIAP1 binds and induces degradation of the activated form of CASP9, but not pro-CASP9. In fish, the activity and regulation of CASP9 remain unknown. In this work, using flounder Paralichthys olivaceus as a representative species, we examined the regulatory mechanism of CASP9 in teleost. P. olivaceus CASP9 (PoCASP9) induced robust apoptosis, which was inhibited by P. olivaceus cIAP1 (PocIAP1). Unlike human cIAP1, PocIAP1 bound both pro- and active PoCASP9 and induced their degradation via the RING domain-involved proteasome pathway. In humans, the adaptor molecule CRADD cannot interact with CASP9. In contrast, P. olivaceus CRADD (PoCRADD) bound both pro- and active PoCASP9 via CARD-CARD interaction and enhanced apoptosis by promoting the cellular levels of pro- and active PoCASP9. Furthermore, PoCRADD abrogated the inhibition of PoCASP9 by PocIAP1 by preventing PocIAP1-PoCASP9 interaction. Together these results reveal a CASP9 regulation mechanism in teleost that differs from that in humans and demonstrate that teleost CASP9 is tightly and directly controlled by both negative and positive regulators that exert a regulation effect both before and after CASP9 activation. These findings advance our understanding of the regulation of CASP9-mediated apoptosis in vertebrates.

Pillararene-Based Stimuli-Responsive Supramolecular Delivery Systems for Cancer Therapy

Cancer poses a significant challenge to global public health, seriously threatening human health and life. Although various therapeutic strategies, such as chemotherapy (CT), radiotherapy, phototherapy, and starvation therapy, are applied to cancer treatment, their limited therapeutic effect, severe side effects, and unsatisfactory drug release behavior need to be carefully considered. Thus, there is an urgent need to develop efficient drug delivery strategies for improving cancer treatment efficacy and realizing on-demand drug delivery. Notably, pillararenes, as an emerging class of supramolecular macrocycles, possess unique properties of highly tunable structures, superior host-guest chemistry, facile modification, and good biocompatibility, which are widely used in cancer therapy to achieve controllable drug release and reduce the toxic side effects on normal tissues under various internal/external stimuli conditions. This review summarizes the recent advance of stimuli-responsive supramolecular delivery systems (SDSs) based on pillararenes for tumor therapy from the perspectives of different assembly methods and hybrid materials, including molecular-scale SDSs, supramolecular nano self-assembly delivery systems, and nanohybrid SDSs. Moreover, the prospects and critical challenges of stimuli-responsive SDSs based on pillararenes for cancer therapy are also discussed.

Water-soluble Pillar[5]arene-based drug candidates for lung and breast cancer

The objective of research was to examine the likely anticancer effectiveness of distinct pillar[5] arene derivatives, ws-penta-P[5] and ws-deca-P[5], on breast and lung cancer cell lines in vitro. To achieve this goal, breast cancer (MCF7) cells, lung cancer (A549) cells, healthy cells (HEK293) were utilized. The IC50 dose of ws-penta-P[5] and ws-deca-P[5] was determined using the MTT method. Both treatment (pillar[5] arene applied) and control (pillar[5] arene not applied) groups were established for all three cell lines. Real-time polymerase chain reaction (qPCR) was used to evaluate changes in gene expression following pillar[5] arene treatment. Flow cytometry analysis was used to determine apoptosis and cell cycle arrest. The treatment group and control group results were compared after the study. The results revealed that in both cell lines treated with ws-deca-P[5], proapoptotic gene expressions were upregulated, while antiapoptotic gene expressions and caspase activation gene expressions were down-regulated. The flow cytometry apoptosis and cell cycle analysis in treatment group compared to the control, it was observed that the apoptosis rate increased in the ws-deca-P[5] and ws-deca-P[5] were shown to cause G0/G1 phase arrest in both cell groups. Results from our study that pillar[5] arene derivatives had the potential for treating breast and lung cancer, and more research is required in this area.

Impacts of potential anticancer agents based on pillar[5]arene for head and neck squamous cell carcinoma cells

PURPOSE

This study was conducted to investigate impacts of potential anticancer (associated with apoptosis and caspase pathways) of two newly synthesized derivatives of pillar[5]arene, named as d-Q-P5 and p-Q-P5, on Squamous cell carcinomas of the head and neck (HNSCC) cells.

MATERIALS AND METHODS

The MTT method was used to determine the IC50 doses of the derivatives on HNSCC cells, and the changes in gene expression were analyzed by real-time polymerase chain reaction (qPCR). The apoptosis change was confirmed by flow cytometry analysis.

RESULTS

The results showed that the d-Q-P5 and p-Q-P5 effectively inhibited the proliferation of the cells by upregulating proapoptotic genes (Bax, Bad, p53, Bak, and Apaf-1) and genes involved in the caspase pathway (Casp2, Casp3, and Casp9), while downregulating the antiapoptotic gene (Bcl-2).

CONCLUSIONS

This study is the first to demonstrate the potential anticancer effects of these two agents on HNSCC cells by positively regulating apoptosis gene expression.